Madrigal Reports Robust 2024 Performance and Plans for Growth
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has released a business update highlighting strong preliminary financial results for 2024 and the ongoing success of its breakthrough treatment, Rezdiffraâ„¢ (resmetirom), …
Madrigal Reports Robust 2024 Performance and Plans for Growth Read More